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mediated reaction whereby IgG and IgM antibodies are directed
against heparin and platelet factor.4 Desensitization is not a
therapeutic option for acute or delayed HIT. Cases have been
reported in which alternative drugs, such as bovine heparin,
ancrod, and argatroban, have been used in place of heparin
when anaphylactoid reactions are suspected; however, their
efficacy has been anecdotal and needs further investigation.4
Two reports exist in the literature in which desensitization
for heparin allergy was attempted before cardiopulmonary by-
pass.2,5 Until more experience is gained with the use of alter-
native anticoagulation agents for cardiopulmonary bypass, we
advocate the use of heparin desensitization as successfully
performed in this case.
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Surgical treatment of recurrent transient ischemic
attacks and hemoptysis in a young man with
multiple pulmonary arteriovenous malformations
Cliff K. Choong, FRACS,a Daniel M. Goodenberger, MD,b,c Daniel Picus, MD,b,d and
Bryan F. Meyers, MD,a St Louis, Mo
Pulmonary arteriovenous malformation (PAVM) is a rarevascular anomaly with an incidence of 2 to 3 per 100,000population.1 We present a patient whose therapy withembolotherapy for PAVMs resulted in recurrent tran-
sient ischemic attacks (TIAs) and massive hemoptysis requiring
treatment by surgical resection.
Clinical Summary
A 17-year-old man with hereditary hemorrhagic telangiectasia
(HHT) had PAVMs incidentally discovered on a chest x-ray film.
Investigations confirmed PAVMs without the presence of associ-
ated bronchial collateral artery. Although his pulse oxygen satu-
ration at rest was 80%, he was asymptomatic. He underwent
embolization therapy with aneurysmal coil placement and cyano-
acrylate glue elsewhere (Figures 1A and 1B). One week later, he
had the first of recurrent TIAs with tingling and numbness in the
right upper extremity. Inves-
tigations including carotid du-
plex scan, echocardiography,
and cerebral CT and MRI did
not reveal any abnormalities. The TIAs were considered to be most
likely caused by emboli originating from clot propagation distal to
the coils. Six months later, he had the first of multiple episodes of
hemoptysis of 16 ounces or more, which were unresponsive to
embolotherapy of several smaller PAVMs. Angiography at our
center showed occlusion of the majority of the PAVMs. A large
bronchial artery was however seen, supplying an area of neovas-
cularization of the inflammatory complex of cyanoacrylate in the
apical segment of the right lower lobe, with rapid filling of the
pulmonary vein, implying arteriovenous shunting (Figure 2A). The
vessel was larger than the largest Ivalon particles, and an attempt
to occlude it by embolotherapy was considered to be potentially
hazardous and unlikely to result in a lasting occlusive effect. A
decision was made to remove the large PAVMs of the right lower
lobe by surgical resection. He underwent an uneventful right lower
lobectomy and at 1-year follow-up, he remained well with no
further TIA or hemoptysis. A transverse section of the resected
lung with coils in the PAVM is shown in Figure 2B.
Discussion
PAVM was first reported in 1897 by Churton in a 12-year-old boy
who had episodes of epistaxis, hemoptysis, and loud pulmonary
systolic bruit.2 At postmortem examination, he was found to have
multiple bilateral PAVMs. More than 80% of PAVMs are con-
genital in origin, and of these 60% to 90% are associated with
HHT.1 Conversely, 15% to 35% of the population with HHT have
a PAVM. The rate of PAVM in our 292 HHT patients was 58%.
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The majority of the patients with PAVMs are asymptomatic.
The clinical presentations range from an incidental finding on a
chest radiograph to hemoptysis, hemothorax, polycythemia, cya-
nosis, and neurologic deficits secondary to paradoxical embolism.
In our experience over a 15-year period, the majority of the
patients with PAVMs are asymptomatic with neurologic compli-
cations being the most common clinical presentations in the forms
of paradoxical embolic stroke (30%) and brain abscess (5%).
Hemoptysis, hemothorax, polycythemia, and cyanosis are all un-
common. The presence of HHT in a patient with a PAVM is of
prognostic value since the patient with coexisting HHT tends to
have worse symptomatology, multiple arteriovenous malforma-
tions, rapid disease progression, and a higher incidence of com-
plication rate.1,3
PAVMs may result in serious complications, which can be
prevented with appropriate treatment. In 1942, Hepburn and Dau-
phinee4 reported the first case of successful surgical removal of a
PAVM with disappearance of the patient’s polycythemia and
clubbing after a pneumonectomy.
Over the decades, surgical treatments of PAVMs were fur-
ther refined to ligation of the pulmonary artery, lobectomy,
segmentectomy, and local excision. Surgery remained the main-
stay of treatment until 1978 when Taylor and coworkers5 re-
ported the first case of successful percutaneous catheterization
and embolization of a PAVM. Embolotherapy has revolution-
Figure 1A. Chest x-ray film showing 2 large PAVMs in the apical
and posterior basal segments of the right lower lobe filled with
numerous long coils.
Figure 1B. Chest CT showing coils in the PAVM in the posterior
basal segment of the right lower lobe.
Figure 2A. Angiography showing a large bronchial artery (8 mm
in size) supplying the PAVM in the apical segment of the right
lower lobe and then rapidly filling the pulmonary vein.
Figure 2B. Cut section of resected right lower lobe showing
multiple coils deposited within a large PAVM.
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ized the treatment of PAVMs by virtually eliminating the need
for surgery and has the advantages of being less invasive, easy
to repeat, and effective.1 In a review of 808 embolotherapy
attempts for 803 PAVMs in 288 patients, the overall success
rate was 99% with no reported mortality.1 The most commonly
encountered complication was self-limiting pleuritic chest pain,
which was seen in up to 13% of patients. Other reported
complications have included pulmonary infarction, air embo-
lism, device migration, myocardial rupture, cerebrovascular
accident, vascular injury, deep vein thrombosis, and pulmonary
hypertension. In our experience of 15 years, apart from pleuritic
chest pain, we only had a single case of balloon migration to a
non-feeding artery and no other complication was encountered.
These excellent results, however, depend upon appropriate
technique, which involves embolization of the feeding vessel
and not the aneurysmal sac, as was done in this case. Cyano-
acrylate glue is not indicated for the treatment of PAVMs as
there is a significant risk of nontarget embolization by using a
liquid agent in a right-to-left shunt. In addition, the tissue
infarction is very extensive with cyanoacrylate glue and that
likely resulted in the recruitment of bronchial collaterals which
led to the life-threatening hemoptysis in this patient. Emboli-
zation in PAVMs should be limited to the abnormal shunt and
rarely, if ever, should result in tissue damage extensive enough
to drive bronchial collateral formation. Surgical resection of
PAVM remains an important option and is indicated in patients
who cannot be embolized, and we have encountered only 3 such
patients over a 15-year period, or those who develop a compli-
cation of embolotherapy such as this reported case. In summary,
we present a young patient with large PAVMs in the right lower
lobe whose inappropriate embolotherapy was complicated by
recurrent TIAs and severe hemoptysis. Surgical resection was
required and resulted in a successful treatment.
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